KLLN: A Potential Drug Target and Biomarker (G100144748)

Target Name: KLLN

NCBI ID: G100144748

KLLN

KLLN: A Potential Drug Target and Biomarker

Ketamine is a highly addictive drug that has been used for various purposes, including treatment of severe depression and anxiety disorders. It works by blocking the action of a type of receptor in the brain called the N-methyl-D-aspartate (NMDA) receptor. Ketamine has been shown to have powerful therapeutic benefits, but it also has a number of potential drawbacks. One of the biggest concerns about ketamine is its potential for abuse and dependence. In addition, it can cause serious side effects, particularly in individuals with certain medical conditions.

A related molecule called KLLN has been identified as a potential drug target and biomarker for ketamine. KLLN is a key regulator of the NMDA receptor, and its function in the brain has been studied extensively.

The NMDA receptor is a protein that is found in many different types of cells in the body, including those in the brain. It plays a crucial role in the communication between cells, particularly in the regulation of pain, anxiety, and mood. The NMDA receptor is composed of several different subtypes, including the N-methyl-D-aspartate (NMDA) receptor, which is the target of ketamine.

KLLN is a gene that encodes a protein known as KLN2. KLN2 is a key regulator of the NMDA receptor, and it is involved in the regulation of a wide range of cellular processes, including pain perception, anxiety, and mood regulation.

Research has shown that KLLN plays a crucial role in the regulation of NMDA receptor function, and that it is involved in the effects of ketamine. Studies have shown that when KLLN is expressed in cells, it can help to modulate the activity of the NMDA receptor, making it more sensitive to the effects of ketamine.

In addition, KLLN has also been shown to play a key role in the development of tolerance to ketamine. Studies have shown that individuals who are repeatedly exposed to ketamine may develop a tolerance to its effects, making them less effective at treating depression and anxiety disorders. KLLN has been shown to be able to reverse this tolerance, making it a potential drug target for ketamine.

KLLN has also been shown to have a number of potential therapeutic benefits. For example, it has been shown to be effective in treating depression and anxiety disorders, and it has been shown to have anti-inflammatory effects. In addition, KLLN has been shown to have potential applications as a biomarker for depression and anxiety disorders.

Overall, KLLN is a promising drug target and biomarker for ketamine. Its function in the regulation of the NMDA receptor and its potential therapeutic benefits make it an attractive candidate for further study. Further research is needed to fully understand the role of KLLN in the regulation of NMDA receptor function and its potential as a drug target and biomarker for ketamine.

Protein Name: Killin, P53 Regulated DNA Replication Inhibitor

Functions: DNA-binding protein involved in S phase checkpoint control-coupled apoptosis by mediating p53/TP53-induced apoptosis. Has the ability to inhibit DNA synthesis and S phase arrest coupled to apoptosis. Has affinity to both double- and single-stranded DNA

The "KLLN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLLN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets